Danaher Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Rainer Blair
- Full Time Employees
- 61,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 2200 Pennsylvania Avenue, NW Washington DC United States of America 20037-1701
- IPO Date
- Dec 29, 1978
- CIK
- 0000313616
- Website
- danaher.com
- Similar Companies
- Business
- Danaher Corporation (NYSE: DHR), founded in 1984 and headquartered in Washington, D.C., operates as a leading global science and technology innovator focused on life sciences and diagnostics. The company conducts business through three primary segments: biotechnology, which develops products and services for therapeutic development including bioprocessing solutions, plasmid DNA, mRNA, proteins, and genomic medicines via brands such as Cytiva, Aldevron, and Abcam; life sciences, offering instruments like mass spectrometers, flow cytometry systems, microscopes, genomics consumables, lab automation, centrifugation, particle characterization, and gene and cell therapy tools; and diagnostics, providing clinical instruments, reagents, consumables, software, and services for disease diagnosis in hospitals, physicians' offices, reference laboratories, and critical care settings through subsidiaries including Cepheid and Beckman Coulter. Danaher serves customers worldwide across biopharmaceutical, research, healthcare, and precision medicine markets, employing approximately 63,000 associates in over 125 countries. Recent developments include the 2023 acquisition of Abcam for proteomic research consumables to accelerate drug discovery; a January 2025 investment partnership with Innovaccer Inc. through Danaher Diagnostics LLC and Danaher Ventures LLC to advance AI-enabled diagnostics and precision medicine; and a May 2025 diagnostic development and commercialization alliance with AstraZeneca to scale next-generation AI-powered diagnostics solutions.
Danaher Boosts Product Portfolio With the Acquisition of Masimo
Implied Volatility Surging for Danaher Stock Options
Strong Performance Continues at DHR's Biotechnology Unit: What's Next?
Here Are Thursday’s Best Wall Street Analyst Research Calls: Callaway Golf, Chewy, CME Group, Danaher, General Dynamics, Intel, SpaceX, Rocket Lab, Toast, and More
Danaher Completes Acquisition of Masimo Corporation
Sirius XM Holdings Set to Join S&P MidCap 400
Baron Discovery Fund Q1 2026: Who Moved The Needle
Here Are Tuesday’s Top Wall Street Analyst Research Calls: CoreWeave, Danaher, Hewlett Packard Enterprise, Intuit, Knight-Swift, Meta Platforms, Starwood Property Trust, Tripadvisor, and More
SCIEX Launches the novus V55 System With SCIEX OS 5.0 Software and AI Enablement Tools
SCIEX Advances the ZenoTOF Line With Platform-Wide Expansions in Software, Integrations, and Key Collaborations
A Look at Danaher Corp (DHR) After 4.3% Gain -- GF Value $236.05 vs Price $180.63
11 'Safer' Dividend Dogs Lead 20 May Barron's 2026 Oil And Blue Chips
Why Is Danaher (DHR) Down 7% Since Last Earnings Report?
Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead?
Here Are Friday’s Top Wall Street Analyst Research Calls: Arista Networks, BWX Technologies, Cisco Systems, Danaher, Doximity, Estee Lauder, Illumina, Texas Roadhouse, Workday, and More
Danaher Corporation (DHR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Danaher to Present at Bank of America Securities Healthcare Conference
Danaher Announces Quarterly Dividend
Masimo Shareholders Approve Acquisition by Danaher
Xylem Q1 Earnings Beat Estimates, Revenues Increase Y/Y